Key result
Platelet-activating factor and tumor necrosis factor may play a pivotal role in deleterious feedback cycles leading to endothelial damage, which may be inhibited by PAF antagonists like BN 52021.
Why the study?
Unregulated inflammatory responses involving platelet-activating factor and tumor necrosis factor may cause endothelial injury and contribute to pathologies like shock, sepsis, ischemia, and asthma.
This review highlights the theoretical potential of platelet-activating factor antagonists in mitigating microvascular immune injury in conditions like shock, sepsis, and ischemia.
Answers are grounded in this paper and cite their sources.
In vitro PAF-TNF priming data are hypothesis-generating; leaves open any role in clinical endothelial injury.
Inflammation is usually a tightly controlled process which confines tissue damage, prevents infection, and assists in cellular regeneration. However, if the inflammatory response becomes unregulated, this normally beneficial local event may escalate into a wider malignant activity, characterized by endothelial injury, excessive cell infiltration, and vascular leakage. Due to the ability of platelet-activating factor and tumor necrosis factor to elicit the release of each other, 'prime' cell responses, and influence the activity of other cytokines, we propose that these two mediators play a pivotal role in the formation of deleterious feedback cycles leading to the above endothelial damage which may underlie pathologies such as shock, sepsis, ischemia, and asthma. Platelet-activating factor antagonists such as BN 52021 inhibit the priming and other effects induced by platelet-activating factor and thus may be of therapeutic value in such conditions.
No takes yet. Share an insight, caveat, or question.
Braquet et al. (2009) conducted a review in Microvascular immune injury, shock, sepsis, ischemia, and asthma. Platelet-activating factor antagonists (e.g., BN 52021) was evaluated. Platelet-activating factor and tumor necrosis factor may play a pivotal role in deleterious feedback cycles leading to endothelial damage, which may be inhibited by PAF antagonists like BN 52021.
Synapse has enriched 10 related papers. Consider them for comparative context: